Tipifarnib in Head and Neck Squamous Cell Carcinoma With
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
/ adverse effects
Female
Head and Neck Neoplasms
/ drug therapy
Humans
Male
Middle Aged
Mutation, Missense
Proto-Oncogene Mas
Proto-Oncogene Proteins p21(ras)
/ genetics
Quinolones
/ adverse effects
Squamous Cell Carcinoma of Head and Neck
/ drug therapy
Young Adult
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333
Informations de publication
Date de publication:
10 06 2021
10 06 2021
Historique:
pubmed:
23
3
2021
medline:
17
7
2022
entrez:
22
3
2021
Statut:
ppublish
Résumé
Mutations in the We enrolled 30 patients with R/M HNSCC in a single-arm, open-label phase II trial of tipifarnib for m Of the 22 patients with HNSCC with high VAF, 20 were evaluable for response at the time of data cutoff. Objective response rate for evaluable patients with high-VAF HNSCC was 55% (95% CI, 31.5 to 76.9). Median progression-free survival on tipifarnib was 5.6 months (95% CI, 3.6 to 16.4) versus 3.6 months (95% CI, 1.3 to 5.2) on last prior therapy. Median overall survival was 15.4 months (95% CI, 7.0 to 29.7). The most frequent treatment-emergent adverse events among the 30 patients with HNSCC were anemia (37%) and lymphopenia (13%). Tipifarnib demonstrated encouraging efficacy in patients with R/M HNSCC with
Identifiants
pubmed: 33750196
doi: 10.1200/JCO.20.02903
pmc: PMC8189627
doi:
Substances chimiques
Antineoplastic Agents
0
MAS1 protein, human
0
Proto-Oncogene Mas
0
Quinolones
0
HRAS protein, human
EC 3.6.5.2
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
tipifarnib
MAT637500A
Banques de données
ClinicalTrials.gov
['NCT02383927']
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1856-1864Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Références
Cancer. 2020 Sep 1;126(17):3972-3981
pubmed: 32557577
Ann Oncol. 2018 Dec 1;29(12):2313-2327
pubmed: 30307465
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Oncologist. 2005 Sep;10(8):565-78
pubmed: 16177281
Nat Rev Cancer. 2018 May;18(5):269-282
pubmed: 29497144
J Immunother Cancer. 2019 Jul 15;7(1):184
pubmed: 31307547
Cancer Discov. 2013 Jul;3(7):770-81
pubmed: 23619168
J Otolaryngol. 1992 Oct;21(5):321-6
pubmed: 1361585
Lancet. 2019 Jan 12;393(10167):156-167
pubmed: 30509740
Lancet Oncol. 2017 May;18(5):570-571
pubmed: 28456585
Comput Struct Biotechnol J. 2019 Jul 26;17:1020-1030
pubmed: 31428295
Science. 2011 Aug 26;333(6046):1157-60
pubmed: 21798893
Oncotarget. 2016 Jul 12;7(28):42988-42995
pubmed: 27119512
Ann Oncol. 2017 Oct 1;28(10):2526-2532
pubmed: 28961833
Nat Rev Clin Oncol. 2019 Nov;16(11):669-683
pubmed: 31189965
J Innate Immun. 2013;5(4):304-14
pubmed: 23571274
Mol Cancer Ther. 2020 Sep;19(9):1784-1796
pubmed: 32727882
Science. 2011 Aug 26;333(6046):1154-7
pubmed: 21798897
Blood. 2014 Jul 10;124(2):277-86
pubmed: 24735964
Cancer Res. 2018 Aug 15;78(16):4642-4657
pubmed: 29760048
Front Cell Dev Biol. 2019 Apr 09;7:52
pubmed: 31024913
Cancer Res. 2001 Jan 1;61(1):131-7
pubmed: 11196150
Clin Cancer Res. 2014 Jun 1;20(11):2933-46
pubmed: 24696319
J Pain Symptom Manage. 2012 Mar;43(3):631-7
pubmed: 21925833
Small GTPases. 2010 Jul;1(1):2-27
pubmed: 21686117
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Ann Oncol. 2014 Oct;25(10):1889-1900
pubmed: 24718888
J Clin Oncol. 2000 Feb;18(4):927-41
pubmed: 10673536
Anticancer Drugs. 2005 Mar;16(3):317-21
pubmed: 15711184
Curr Opin Oncol. 2001 Nov;13(6):470-6
pubmed: 11673687
Leukemia. 2011 Oct;25(10):1543-7
pubmed: 21625235
Nat Commun. 2016 Dec 08;7:13665
pubmed: 27929064
Arch Otolaryngol Head Neck Surg. 1994 Jul;120(7):755-60
pubmed: 7912510
Nature. 2012 Sep 27;489(7417):519-25
pubmed: 22960745